PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM ...
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.1135
https://www.valueinhealthjournal.com/article/S1098-3015(19)33513-2/fulltext
Section Title :
Section Order :
10994
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33513-2&doi=10.1016/j.jval.2019.09.1135